Souhaitez-vous accéder aux communiqués récents ?

The investment will support the upgrade and retrofit of the existing facility and enhance Novo Nordisk’s capacity to manufacture oral GLP-1s outside the US

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR  FOURTH QUARTER / FULL YEAR | 2025 Q4 2025 sales increased by 1 % in local currencies1 to CHF 1.028 billion due to strong volume growth in Catalysts and...

Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities

The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84...

Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual...

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.

Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...

Finnvera Group, Stock Exchange Release 12 February 2026 Report of the Board of Directors and Financial Statements 2025 The volume of granted export financing was extremely high, domestic financing...